(Q37738464)

22 August 2017

1 reference

title

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia (English)

1 reference

22 August 2017

main subject

chronic myeloid leukemia

0 references

1 reference

3

Jorge Cortes

1 reference

22 August 2017

Ronan Swords

1

1 reference

22 August 2017

Yesid Alvarado

series ordinal

2

1 reference

22 August 2017

Francis J Giles

series ordinal

4

1 reference

22 August 2017

publication date

1 May 2007

1 reference

Current hematologic malignancy reports

22 August 2017

published in

1 reference

22 August 2017

volume

2

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

83-88

1 reference

Inhibition of c-fms by imatinib: expanding the spectrum of treatment.

22 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11899-007-0012-4

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

21 January 2018

1 reference

12 December 2020

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

12 December 2020

Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells

1 reference

12 December 2020

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

1 reference

12 December 2020

Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.

1 reference

12 December 2020

Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant

1 reference

12 December 2020

Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl

1 reference

12 December 2020

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

1 reference

12 December 2020

Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells

1 reference

12 December 2020

The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha.

1 reference

12 December 2020

Signaling by ABL oncogenes through cyclin D1.

1 reference

12 December 2020

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

1 reference

12 December 2020

BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.

1 reference

12 December 2020

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

12 December 2020

BCR-ABL delays apoptosis upstream of procaspase-3 activation

1 reference

12 December 2020

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

12 December 2020

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity

1 reference

12 December 2020

Bcr/Abl expression stimulates integrin function in hematopoietic cell lines

1 reference

12 December 2020

ARG tyrosine kinase activity is inhibited by STI571.

1 reference

12 December 2020

BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein

1 reference

12 December 2020

The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation

1 reference

12 December 2020

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

1 reference

12 December 2020

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

12 December 2020

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

1 reference

12 December 2020

C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis

1 reference

12 December 2020

BCR/ABL induces multiple abnormalities of cytoskeletal function

1 reference

12 December 2020

An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

1 reference

12 December 2020

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

1 reference

12 December 2020

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

1 reference

12 December 2020

Dominant negative MYC blocks transformation by ABL oncogenes

1 reference

12 December 2020

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

12 December 2020

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

12 December 2020

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

12 December 2020

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

12 December 2020

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

1 reference

12 December 2020

The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway

1 reference

12 December 2020

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene

1 reference

12 December 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene

1 reference

12 December 2020

10.1007/S11899-007-0012-4

Identifiers

DOI

1 reference

22 August 2017

1 reference